Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Lishi Jiedu formula is a Traditional Chinese Medicine (TCM) herbal composition developed by the Nanjing Hospital of Integrated Traditional Chinese and Western Medicine. It is primarily used for the prevention of postoperative recurrence in patients with colorectal adenoma, specifically those diagnosed with the spleen deficiency and dampness-toxin TCM syndrome. The formula's mechanism of action is being investigated for its ability to modulate the IL-6/JAK/STAT3 signaling pathway, which plays a critical role in the inflammatory response and the development of colorectal tumors. By targeting these pathways, the formula aims to inhibit the recurrence of adenomatous polyps following surgical removal.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianpi Lishi Jiedu formula.